Health care workers at Vanderbilt University Medical Center at high risk of exposure to COVID-19 can participate in a randomized, controlled clinical trial testing the effectiveness of the drug hydroxychloroquine (HCQ) in preventing infection.

A team of Vanderbilt researchers constructed polygenic risk scores (PRS) based on genomic variants associated with eight common cancers and concluded they could potentially be used for personalized risk assessments.

The Medical Scientist Training Program has been intentional in approaching the challenges presented by COVID-19.

The NCI program project grant is supporting multiple projects that aim to define fundamental biological principles about extracellular RNA signaling and the development and aggressiveness of colorectal cancer, the second leading cause of cancer death in the United States.

High levels of stress and anxiety can be debilitating, especially for health care providers on the front lines of the COVID-19 pandemic. But there are ways they can protect themselves and their ability to provide the best and most compassionate care.

VUMC is playing a key role in a national effort to establish a registry of U.S. health care workers and test whether the anti-malarial drug hydroxychloroquine (HCQ) will protect them, their patients and their families from COVID-19.

A Vanderbilt University Medical Center interim analysis shows that there appears to be a considerable length of time before a subset of people develop inflammatory, scarring lung diseases where there is radiologically detectable evidence they will develop lung disease.